Accord Healthcare recalled 54,432 bottles of Levothyroxine Sodium Tablets on September 16, 2025. The tablets were found to be subpotent during stability testing. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
Consumers and healthcare providers should stop using this product immediately. Contact ACCORD HEALTHCARE, INC. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Levothyroxine Sodium Tablets, USP, 88 mcg, packaged in bottles of 90 tablets. The affected lot number is D2300045, with an expiration date of December 31, 2025. These products were distributed nationwide.
The tablets were tested and found to have assay content below the approved specification range. This subpotency can lead to inadequate treatment for patients requiring thyroid hormone replacement.
No specific incidents or injuries have been reported related to this recall. However, the risk of inadequate treatment remains a serious concern.
Stop using the recalled Levothyroxine Sodium Tablets immediately. Contact Accord Healthcare or your healthcare provider for further guidance and potential arrangements for return and refund.
For more information, contact Accord Healthcare at 1-800-XXXX-XXXX or visit their website at www.accordhealthcare.com.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.